Drugs / AMR-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00313339 | Mar 2006 → Mar 2009 | coronary artery disorder, myocardial infarction | Emory University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMR-001 | “Therefore, we propose to evaluate the safety and efficacy of a CD34+ selected stem cell product (AMR-001), administered through the infarct related coronary artery 6 to 9 days...” NCT00313339 ↗ |
| Modality | Cell therapy | “CD34+ selected stem cell product” NCT00313339 ↗ |
| Route | Other | “administered through the infarct related coronary artery” NCT00313339 ↗ |